{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=24", "query": { "intervention": "placebo oral capsules", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 2673, "total_pages": 268, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+oral+capsules&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-16T10:53:57.746Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03797521", "title": "A Study in Patients With Trichotillomania", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Trichotillomania" ], "interventions": [ { "name": "SXC-2023", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Promentis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 128, "start_date": "2018-12-19", "completion_date": "2019-12-16", "has_results": false, "last_update_posted_date": "2021-10-28", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 13, "location_summary": "Pico Rivera, California • Riverside, California • North Miami, Florida + 10 more", "locations": [ { "city": "Pico Rivera", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "North Miami", "state": "Florida" }, { "city": "Decatur", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03797521" }, { "nct_id": "NCT06097676", "title": "An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Abuse Potential" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Alprazolam 2 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg", "type": "DRUG" }, { "name": "Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arbor Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 86, "start_date": "2021-09-28", "completion_date": "2022-06-30", "has_results": true, "last_update_posted_date": "2024-08-12", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06097676" }, { "nct_id": "NCT01111552", "title": "Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Major Depressive Disorder (MDD)" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 237, "start_date": "2010-07-29", "completion_date": "2011-09-27", "has_results": true, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Carson, California + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Carson", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Imperial", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111552" }, { "nct_id": "NCT00323414", "title": "Polyunsaturated Fatty Acids (PUFA) in Diabetic Fatty Liver", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Fatty Liver" ], "interventions": [ { "name": "Polyunsaturated fatty acid (Opti-EPA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2006-04", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2018-02-23", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00323414" }, { "nct_id": "NCT02708355", "title": "Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heartburn" ], "interventions": [ { "name": "Esomeprazole 20 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "22 Years to 65 Years" }, "enrollment_count": 55, "start_date": "2016-01", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-04-19", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 2, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT02708355" }, { "nct_id": "NCT05583526", "title": "A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stable Nonsegmental Vitiligo", "Active Nonsegmental Vitiligo" ], "interventions": [ { "name": "Ritlecitinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 607, "start_date": "2022-12-01", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 46, "location_summary": "Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Encinitas", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05583526" }, { "nct_id": "NCT03049735", "title": "LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heavy Menstrual Bleeding", "Uterine Fibroid" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate", "type": "DRUG" }, { "name": "Estradiol/norethindrone acetate placebo", "type": "DRUG" }, { "name": "Relugolix placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Myovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 388, "start_date": "2017-04-26", "completion_date": "2020-08-24", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 76, "location_summary": "Andalusia, Alabama • Mobile, Alabama • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Andalusia", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Mesa", "state": "California" }, { "city": "Lomita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03049735" }, { "nct_id": "NCT00248547", "title": "Aprepitant in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "aprepitant", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "ondansetron", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2004-05", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00248547" }, { "nct_id": "NCT04575038", "title": "CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "COVID-19 Infection" ], "interventions": [ { "name": "Brequinar", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clear Creek Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2020-11-19", "completion_date": "2021-04-28", "has_results": true, "last_update_posted_date": "2022-04-19", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 14, "location_summary": "Homewood, Alabama • Long Beach, California • Doral, Florida + 11 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Doral", "state": "Florida" }, { "city": "Somers Point", "state": "New Jersey" }, { "city": "Monroe", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04575038" }, { "nct_id": "NCT06673238", "title": "A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "ABBV-722", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 95, "start_date": "2024-10-29", "completion_date": "2026-06-25", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-16T10:53:57.746Z", "location_count": 2, "location_summary": "Cypress, California • Grayslake, Illinois", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06673238" } ] }